DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus

Phase 2

Terminated

Conditions: Diabetes Mellitus

Interventions: Drug: Placebo
Drug: SYR-619
Drug: Alogliptin

First Posted Date: 2008-09-30

Last Posted Date: 2012-05-21

Lead Sponsor: Takeda

Target Recruit Count: 82

Registration Number: NCT00763347

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Pioglitazone and azilsartan
Drug: Pioglitazone

First Posted Date: 2008-09-30

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 704

Registration Number: NCT00762736

Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Phase 3

Terminated

Conditions: Diabetes Mellitus

Interventions: Drug: Placebo
Drug: TAK-559

First Posted Date: 2008-09-30

Last Posted Date: 2012-11-12

Lead Sponsor: Takeda

Target Recruit Count: 8

Registration Number: NCT00762684

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Ramipril
Drug: Azilsartan medoxomil

First Posted Date: 2008-09-26

Last Posted Date: 2012-11-15

Lead Sponsor: Takeda

Target Recruit Count: 885

Registration Number: NCT00760214

Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: TAK-715 and methotrexate
Drug: Methotrexate

First Posted Date: 2008-09-26

Last Posted Date: 2010-06-11

Lead Sponsor: Takeda

Target Recruit Count: 432

Registration Number: NCT00760864

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

Phase 2

Completed

Conditions: Diabetic Neuropathies

Interventions: Drug: TAK-583
Drug: Placebo

First Posted Date: 2008-09-26

Last Posted Date: 2016-06-22

Lead Sponsor: Takeda

Target Recruit Count: 338

Registration Number: NCT00760955

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: SYR-472
Drug: Placebo
Drug: Sitagliptin

First Posted Date: 2008-09-26

Last Posted Date: 2016-06-22

Lead Sponsor: Takeda

Target Recruit Count: 386

Registration Number: NCT00760344

Efficacy and Safety of TAK-783 in Subjects With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: TAK-783 and methotrexate
Drug: Methotrexate

First Posted Date: 2008-09-26

Last Posted Date: 2010-06-11

Lead Sponsor: Takeda

Target Recruit Count: 224

Registration Number: NCT00760968

Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.

Phase 3

Terminated

Conditions: Diabetes Mellitus

Interventions: Drug: TAK-559 and glyburide
Drug: Glyburide

First Posted Date: 2008-09-25

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 447

Registration Number: NCT00759720

Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: Azilsartan
Drug: Placebo
Drug: Olmesartan

First Posted Date: 2008-09-25

Last Posted Date: 2010-06-22

Lead Sponsor: Takeda

Target Recruit Count: 555

Registration Number: NCT00759551

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy